Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

BACKGROUND & AIMS: Higher serum bile acid levels are associated with an increased risk of cirrhosis and liver-related morbidity and mortality. Herein, we report secondary analyses of aldafermin, an engineered analogue of the gut hormone fibroblast growth factor 19, on the circulating bile acid p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanyal, Arun J., Ling, Lei, Beuers, Ulrich, DePaoli, Alex M., Lieu, Hsiao D., Harrison, Stephen A., Hirschfield, Gideon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056274/
https://www.ncbi.nlm.nih.gov/pubmed/33898959
http://dx.doi.org/10.1016/j.jhepr.2021.100255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056274/
https://www.ncbi.nlm.nih.gov/pubmed/33898959
http://dx.doi.org/10.1016/j.jhepr.2021.100255

Ejemplares similares